[1]程家松.替雷利珠单抗联合DP化疗方案治疗晚期肺癌的临床效果及对免疫功能的影响[J].医学信息,2023,36(22):136-139.[doi:10.3969/j.issn.1006-1959.2023.22.031]
　CHENG Jia-song.Clinical Effect of Tirelizumab Combined with DP Chemotherapy in the Treatment of Advanced Lung Cancer and its Effect on Immune Function[J].Journal of Medical Information,2023,36(22):136-139.[doi:10.3969/j.issn.1006-1959.2023.22.031]
点击复制

替雷利珠单抗联合DP化疗方案治疗晚期肺癌的临床效果及对免疫功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年22期
页码:
136-139
栏目:
论著
出版日期:
2023-11-15

文章信息/Info

Title:
Clinical Effect of Tirelizumab Combined with DP Chemotherapy in the Treatment of Advanced Lung Cancer and its Effect on Immune Function
文章编号:
1006-1959（2023）22-0136-04
作者:
程家松
（鄱阳湖医院肿瘤科，江西 鄱阳 333100）
Author(s):
CHENG Jia-song
(Department of Oncology,Poyang Lake Hospital,Poyang 333100,Jiangxi,China)
关键词:
替雷利珠单抗; DP化疗; 晚期肺癌; 免疫功能
Keywords:
Tireilizumab; DP chemotherapy; Advanced lung cancer; Immune function
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.22.031
文献标志码:
A
摘要:
目的 观察替雷利珠单抗联合DP化疗方案治疗晚期肺癌的疗效及对免疫功能的影响。方法 选取2020年1月-2021年9月我院接诊的60例晚期肺癌患者为研究对象，采用随机数字表法分为对照组和观察组，各30例。对照组应用DP化疗方案治疗，观察组在对照组基础上联合替雷利珠单抗治疗，比较两组近期疗效、免疫功能指标（CD3+、CD4+、CD4+/CD8+）、血清肿瘤标志物[癌胚抗原（CEA）、糖抗原125（CA125）]、毒副反应、生存期。结果 观察组客观缓解率、疾病控制率均高于对照组（P＜0.05）；两组治疗后CD3+、CD4+、CD4+/CD8+均高于治疗前，且观察组高于对照组（P＜0.05）；两组治疗后CEA、CA125水平低于治疗前，且观察组低于对照组（P＜0.05）；观察组白细胞减少、恶心呕吐、脱发、骨髓抑制发生率与对照组比较，差异无统计学意义（P＞0.05）；随访1年，观察组平均生存期大于对照组（P＜0.05）。结论 替雷利珠单抗联合DP化疗方案可一定程度提高晚期肺癌患者的疾病控制率和客观缓解率，改善免疫功能，降低肿瘤标志物水平，延长患者生存期，且不会增加毒副反应，具有应用安全性、有效性。
Abstract:
Objective To observe the curative effect and influence on immune function of terelizumab combined with DP chemotherapy in the treatment of advanced lung cancer.Methods A total of 60 patients with advanced lung cancer who were admitted to our hospital from January 2020 to September 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 30 patients in each group. The control group was treated with DP chemotherapy regimen, and the observation group was treated with tirelizumab on the basis of the control group. The short-term efficacy, immune function indexes (CD3+, CD4+, CD4+/CD8+), serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125)], toxic and side effects, and survival time were compared between the two groups.Results The objective remission rate and disease control rate of the observation group were higher than those of the control group (P<0.05). After treatment, CD3+, CD4+ and CD4+/CD8+ in the two groups were higher than those before treatment, and those in the observation group were higher than the control group (P<0.05). After treatment, the levels of CEA and CA125 in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). There was no significant difference in the incidence of leukopenia, nausea and vomiting, alopecia and bone marrow suppression between the observation group and the control group (P>0.05). After 1 year of follow-up, the average survival time of the observation group was longer than that of the control group (P<0.05).Conclusion Tenrealizumab combined with DP chemotherapy can improve the disease control rate and objective remission rate of patients with advanced lung cancer to a certain extent, improve immune function, reduce the level of tumor markers, prolong the survival time of patients, and will not increase toxic and side effects, with application safety and effectiveness.

参考文献/References:

[1]苏大伟,张小利.艾迪注射液联合GP化疗方案治疗非小细胞肺癌的临床观察[J].肿瘤基础与临床,2019,32(1):31-34.[2]Hu Z,Bi G,Sui Q,et al.Analyses of multi -omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma [J].Int Immunopharmacol,2020,88(12):106-110.[3]周彩存,王洁,步宏,等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019 年版)[J].中国肺癌杂志,2020,23(2):7-18.[4]林冬梅,陆舜.非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识[J].中国肺癌杂志,2020,23(9):733-740.[5]吴岑,黄志扬,伍伯聪,等.阿昔替尼联合替雷利珠单抗在一线靶向治疗失败的晚期肾癌患者中的疗效观察[J].中国临床药理学杂志,2021,37(12):421-429.[6]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.[7]唐武兵,杨文,陈健智,等.尼妥珠单抗联合调强适形放疗及化疗治疗局部晚期肺鳞癌的研究[J].医学信息,2019,32(20):1-4.[8]高省伟.肝动脉介入化疗栓塞术联合还原型谷胱甘肽治疗在老年晚期肝癌患者中的应用[J].新疆医学,2020,50(1):60-63.[9]李山岭,王杰,陈素芳,等.尼妥珠单抗靶向治疗联合TC化疗方案治疗晚期非小细胞肺癌患者的效果观察[J].河南医学研究,2018,27(13):2369-2370.[10]Wang J,Fei KK,Jing H,etal.Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit[J].MAbs,2019,11(8):1443-1451.[11]胡梦雪,高红婷,宁智鹏,等.帕博利珠单抗单药与化疗二线治疗晚期或转移性食管癌的成本-效果分析[J].中国医院药学杂志,2022,42(3):318-323.[12]张倩,王伟,徐春华.贝伐珠单抗联合培美曲塞/顺铂方案一线治疗EGFR野生型晚期肺腺癌的效果分析[J].临床肿瘤学杂志,2019,24(4):359-363．[13]周泽军,谢海燕,侯志波,等.白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的疗效及安全性[J].江苏医药,2021,47(11):1169-1173．[14]戴丽,王小华,杨万春,等.贝伐珠单抗联合TP化疗方案对晚期非鳞癌非小细胞肺癌患者免疫功能、生活质量和血清肿瘤标志物的影响[J].现代生物医学进展,2021,21(11):2174-2178.[15]石磊.吉非替尼联合GP化疗方案对晚期非小细胞肺癌患者的影响[J].实用中西医结合临床,2019,19(5):48-50.[16]Song Y,Wu J,Chen X,et al.A single-arm,multicenter, phase Ⅱstudy of camrelizumab in relapsed or refractory classical hodgkin lymphoma[J].Clin Cancer Res,2019,25(24):7363-7369.[17]叶炳南,谢石兰.替雷利珠单抗联合化疗对非小细胞肺癌的疗效及影响因素[J].实用中西医结合临床,2022,22(24):91-93,120.[18]Liu SY,Wu YL.Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)[J].Expert Opin Investig Drugs,2020,29(12):1355-1364.[19]Wang J,Lu S,Yu X,et al.Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial[J].JAMA Oncol,2021,7(5):709-717.[20]斯日古楞,杨宏,乌日汗,等.晚期非小细胞肺癌化疗及化疗联合吉非替尼治疗的临床疗效及药物经济学分析[J].中国药物经济学,2019,14(5):45-49.[21]陈香梅,刘太锋,杨明,等.不同免疫检查点抑制剂联合化疗治疗非小细胞肺癌的疗效及对肿瘤标志物水平的影响[J].中国肿瘤临床与康复,2022,29(7):774-778.

更新日期/Last Update: 1900-01-01